INBX Latest Headlines

Inhibrx Biosciences Holds 2026 Virtual Annual Shareholder Meeting

at www.tipranks.com (Wed, 3-Jun 5:14 PM)

INBRX-106 Combination Doubles Response Rate in Early HNSCC Study, Showing Clear Clinical Benefit Over Standard PD-1 Monotherapy

Market Chameleon (Mon, 11-May 8:16 AM)

INBX Highlights: Ozekibart Shows Robust Disease Control Rate of 87% in Late-Line Colorectal Cancer—Durable Responses Outpace Historical Norms

Market Chameleon (Wed, 22-Apr 10:28 AM)

INBX’s Ozekibart Delivers 20% Response Rate and 87% Disease Control in Late-Line Colorectal Cancer—Durable Results in Tough-to-Treat Patients

Market Chameleon (Wed, 22-Apr 7:34 AM)

Inhibrx Cuts R&D Costs Sharply as Two Clinical Trials Push Toward Key 2026 Milestones

Market Chameleon (Fri, 20-Mar 10:59 AM)